Table 2.
Number of cycles of therapy, objective response rate (ORR) and median progression-free survival (PFS) in the first line of treatment depending on the used chemotherapy regimen.
| Scheme | Median Number of Cycles (range) | ORR % (n) | Median PFS (95% CI) [Months] | HR (95% CI) | p |
|---|---|---|---|---|---|
| ADIC (n = 47) | 5 (1–11) | 27.6% (13) | 4.3 (2.3–6.3) | 1 | |
| HD-IFO (n = 40) | 4 (1–13) | 25.0% (8) | 3.2 (2.7–3.9) | 1.28 (0.83–1.98) | 0.260 |
| EI (n = 17) | 4 (2–12) | 23.5% (7) | 4.6 (0–10.6) | 0.97 (0.56–1.73) | 0.961 |
| AI (n = 6) | 6 (3–9) | 66.7% (4) | 10.1 (4.3–20.6) | 0.30 (0.09–0.96) | 0.042 |
| AP3 (n = 5) | 8 (2–9) | 0% | 5.9 (5.6–6.3) | 0.87 (0.34–2.20) | 0.765 |
ADIC, doxorubicin + dacarbazine; AI, doxorubicin + ifosfamide; AP3, doxorubicin + cisplatin; EI, etoposide + ifosfamide; HD-IFO, high-dose ifosfamide.